Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Determination and characterization of a cannabinoid receptor in rat brain.
Dynamic regulatory network controlling TH17 cell differentiation.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Vitamin D intake and incidence of multiple sclerosis.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
A high-density screen for linkage in multiple sclerosis.
Saccadic intrusions: review and update.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
4-aminopyridine toxicity: a case report and review of the literature.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Roche's MabThera approved for two vasculitis indications in UK
Fingolimod is a potential novel therapy for multiple sclerosis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Extoxnet (extension toxicology network), 4-aminopyridine

Pages